In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)
Zidovudine and foscarnet each have antiretroviral activity against human immunodeficiency virus (HIV) and, when combined in vitro, inhibit HIV replication in an additive or synergistic fashion. To determine if an in vivo additive or synergistic antiretroviral effect might result from combined therap...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1991-06, Vol.163 (6), p.1219-1222 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1222 |
|---|---|
| container_issue | 6 |
| container_start_page | 1219 |
| container_title | The Journal of infectious diseases |
| container_volume | 163 |
| creator | Jacobson, Mark A. van der Horst, Charles Causey, Dennis M. Dehlinger, Marjorie Hafner, Richard Mills, John |
| description | Zidovudine and foscarnet each have antiretroviral activity against human immunodeficiency virus (HIV) and, when combined in vitro, inhibit HIV replication in an additive or synergistic fashion. To determine if an in vivo additive or synergistic antiretroviral effect might result from combined therapy, six symptomatic HIV-infected patients were studied who had persistently quantifiable serum HIV p24 antigen despite 9–27 weeks of full-dose oral zidovudine therapy (1200mg/day). These patients were given intravenous foscarnet (30mg/kgevery 8 h) for 2 weeks with continued oral zidovudine for 14days, followed by zidovudine alone for 6 months. Serum p24 antigen concentrations decreased in all six patients during the period of combined therapy by a mean 53% (P = .(05). Subsequently, serum p24 antigen levels rose to the baseline value in four patients after 4–14 weeks. As predicted from in vitro studies, combined treatment with zidovudine and foscamet resulted in an additive in vivo effect, but the effect was transient. |
| doi_str_mv | 10.1093/infdis/163.6.1219 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_80571219</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30132536</jstor_id><sourcerecordid>30132536</sourcerecordid><originalsourceid>FETCH-LOGICAL-c302t-de36bff962fdd0080df6b3cdbf097448b4f3b46a7e7f3f71cc24b4f73084b8a03</originalsourceid><addsrcrecordid>eNqFkc9u1DAQhy0EKkvhATgg-YTgkO04TuzkuFq1zYpKcFhQ1Yvl-I9w2diL7azY1-CJySqr9shprPlmvpH8Q-g9gSWBll45b7VLV4TRJVuSkrQv0ILUlBeMEfoSLQDKsiBN275Gb1J6BICKMn6BLkhTNsDrBfq78fiHOwS80tpldzB45bOLJsdwcFHu8LW1RmUcLF6HoXfeaPzgdDiMenpj6TW-CUnJ6E3G258myv0R2xBxNw7S480wjD5oY51yxqvjdCuOCW_8SeqCx59W6-0t_hZDDirsMNT081v0yspdMu_O9RJ9v7nerrvi7uvtZr26KxSFMhfaUNZb27LSag3QgLasp0r3FlpeVU1fWdpXTHLDLbWcKFVWU49TaKq-kUAv0cfZu4_h92hSFoNLyux20pswJtFAzU9_-t9BwoBVlJyMZB5UMaQUjRX76AYZj4KAOAUm5sCmDSqYOMs_nOVjPxj9vDEn9MwfUw7xCVMgtKwpm3gxc5ey-fPEZfwlGKe8Ft39g2Dbjndf7isB9B8Sf6zj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16064310</pqid></control><display><type>article</type><title>In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><creator>Jacobson, Mark A. ; van der Horst, Charles ; Causey, Dennis M. ; Dehlinger, Marjorie ; Hafner, Richard ; Mills, John</creator><creatorcontrib>Jacobson, Mark A. ; van der Horst, Charles ; Causey, Dennis M. ; Dehlinger, Marjorie ; Hafner, Richard ; Mills, John</creatorcontrib><description>Zidovudine and foscarnet each have antiretroviral activity against human immunodeficiency virus (HIV) and, when combined in vitro, inhibit HIV replication in an additive or synergistic fashion. To determine if an in vivo additive or synergistic antiretroviral effect might result from combined therapy, six symptomatic HIV-infected patients were studied who had persistently quantifiable serum HIV p24 antigen despite 9–27 weeks of full-dose oral zidovudine therapy (1200mg/day). These patients were given intravenous foscarnet (30mg/kgevery 8 h) for 2 weeks with continued oral zidovudine for 14days, followed by zidovudine alone for 6 months. Serum p24 antigen concentrations decreased in all six patients during the period of combined therapy by a mean 53% (P = .(05). Subsequently, serum p24 antigen levels rose to the baseline value in four patients after 4–14 weeks. As predicted from in vitro studies, combined treatment with zidovudine and foscamet resulted in an additive in vivo effect, but the effect was transient.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/163.6.1219</identifier><identifier>PMID: 1828075</identifier><language>eng</language><publisher>United States: University Chicago Press</publisher><subject>Administration, Oral ; AIDS ; AIDS related complex ; AIDS/HIV ; Antigens ; Antiretrovirals ; Antiviral Agents - administration & dosage ; Antiviral Agents - therapeutic use ; Antivirals ; Blood plasma ; Dosage ; Drug Therapy, Combination ; Follow-Up Studies ; Foscarnet ; Gene Products, gag - blood ; HIV ; HIV Antigens - blood ; HIV Core Protein p24 ; HIV Infections - drug therapy ; Humans ; Infections ; Infusions, Intravenous ; Lymphocytes ; Major Articles ; Phosphonoacetic Acid - administration & dosage ; Phosphonoacetic Acid - analogs & derivatives ; Phosphonoacetic Acid - therapeutic use ; Viral Core Proteins - blood ; Zidovudine - administration & dosage ; Zidovudine - therapeutic use</subject><ispartof>The Journal of infectious diseases, 1991-06, Vol.163 (6), p.1219-1222</ispartof><rights>Copyright 1991 University of Chicago</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c302t-de36bff962fdd0080df6b3cdbf097448b4f3b46a7e7f3f71cc24b4f73084b8a03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30132536$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30132536$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1828075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jacobson, Mark A.</creatorcontrib><creatorcontrib>van der Horst, Charles</creatorcontrib><creatorcontrib>Causey, Dennis M.</creatorcontrib><creatorcontrib>Dehlinger, Marjorie</creatorcontrib><creatorcontrib>Hafner, Richard</creatorcontrib><creatorcontrib>Mills, John</creatorcontrib><title>In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Zidovudine and foscarnet each have antiretroviral activity against human immunodeficiency virus (HIV) and, when combined in vitro, inhibit HIV replication in an additive or synergistic fashion. To determine if an in vivo additive or synergistic antiretroviral effect might result from combined therapy, six symptomatic HIV-infected patients were studied who had persistently quantifiable serum HIV p24 antigen despite 9–27 weeks of full-dose oral zidovudine therapy (1200mg/day). These patients were given intravenous foscarnet (30mg/kgevery 8 h) for 2 weeks with continued oral zidovudine for 14days, followed by zidovudine alone for 6 months. Serum p24 antigen concentrations decreased in all six patients during the period of combined therapy by a mean 53% (P = .(05). Subsequently, serum p24 antigen levels rose to the baseline value in four patients after 4–14 weeks. As predicted from in vitro studies, combined treatment with zidovudine and foscamet resulted in an additive in vivo effect, but the effect was transient.</description><subject>Administration, Oral</subject><subject>AIDS</subject><subject>AIDS related complex</subject><subject>AIDS/HIV</subject><subject>Antigens</subject><subject>Antiretrovirals</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Antivirals</subject><subject>Blood plasma</subject><subject>Dosage</subject><subject>Drug Therapy, Combination</subject><subject>Follow-Up Studies</subject><subject>Foscarnet</subject><subject>Gene Products, gag - blood</subject><subject>HIV</subject><subject>HIV Antigens - blood</subject><subject>HIV Core Protein p24</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Infections</subject><subject>Infusions, Intravenous</subject><subject>Lymphocytes</subject><subject>Major Articles</subject><subject>Phosphonoacetic Acid - administration & dosage</subject><subject>Phosphonoacetic Acid - analogs & derivatives</subject><subject>Phosphonoacetic Acid - therapeutic use</subject><subject>Viral Core Proteins - blood</subject><subject>Zidovudine - administration & dosage</subject><subject>Zidovudine - therapeutic use</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc9u1DAQhy0EKkvhATgg-YTgkO04TuzkuFq1zYpKcFhQ1Yvl-I9w2diL7azY1-CJySqr9shprPlmvpH8Q-g9gSWBll45b7VLV4TRJVuSkrQv0ILUlBeMEfoSLQDKsiBN275Gb1J6BICKMn6BLkhTNsDrBfq78fiHOwS80tpldzB45bOLJsdwcFHu8LW1RmUcLF6HoXfeaPzgdDiMenpj6TW-CUnJ6E3G258myv0R2xBxNw7S480wjD5oY51yxqvjdCuOCW_8SeqCx59W6-0t_hZDDirsMNT081v0yspdMu_O9RJ9v7nerrvi7uvtZr26KxSFMhfaUNZb27LSag3QgLasp0r3FlpeVU1fWdpXTHLDLbWcKFVWU49TaKq-kUAv0cfZu4_h92hSFoNLyux20pswJtFAzU9_-t9BwoBVlJyMZB5UMaQUjRX76AYZj4KAOAUm5sCmDSqYOMs_nOVjPxj9vDEn9MwfUw7xCVMgtKwpm3gxc5ey-fPEZfwlGKe8Ft39g2Dbjndf7isB9B8Sf6zj</recordid><startdate>199106</startdate><enddate>199106</enddate><creator>Jacobson, Mark A.</creator><creator>van der Horst, Charles</creator><creator>Causey, Dennis M.</creator><creator>Dehlinger, Marjorie</creator><creator>Hafner, Richard</creator><creator>Mills, John</creator><general>University Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199106</creationdate><title>In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)</title><author>Jacobson, Mark A. ; van der Horst, Charles ; Causey, Dennis M. ; Dehlinger, Marjorie ; Hafner, Richard ; Mills, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c302t-de36bff962fdd0080df6b3cdbf097448b4f3b46a7e7f3f71cc24b4f73084b8a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Administration, Oral</topic><topic>AIDS</topic><topic>AIDS related complex</topic><topic>AIDS/HIV</topic><topic>Antigens</topic><topic>Antiretrovirals</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Antivirals</topic><topic>Blood plasma</topic><topic>Dosage</topic><topic>Drug Therapy, Combination</topic><topic>Follow-Up Studies</topic><topic>Foscarnet</topic><topic>Gene Products, gag - blood</topic><topic>HIV</topic><topic>HIV Antigens - blood</topic><topic>HIV Core Protein p24</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Infections</topic><topic>Infusions, Intravenous</topic><topic>Lymphocytes</topic><topic>Major Articles</topic><topic>Phosphonoacetic Acid - administration & dosage</topic><topic>Phosphonoacetic Acid - analogs & derivatives</topic><topic>Phosphonoacetic Acid - therapeutic use</topic><topic>Viral Core Proteins - blood</topic><topic>Zidovudine - administration & dosage</topic><topic>Zidovudine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jacobson, Mark A.</creatorcontrib><creatorcontrib>van der Horst, Charles</creatorcontrib><creatorcontrib>Causey, Dennis M.</creatorcontrib><creatorcontrib>Dehlinger, Marjorie</creatorcontrib><creatorcontrib>Hafner, Richard</creatorcontrib><creatorcontrib>Mills, John</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jacobson, Mark A.</au><au>van der Horst, Charles</au><au>Causey, Dennis M.</au><au>Dehlinger, Marjorie</au><au>Hafner, Richard</au><au>Mills, John</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053)</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1991-06</date><risdate>1991</risdate><volume>163</volume><issue>6</issue><spage>1219</spage><epage>1222</epage><pages>1219-1222</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><abstract>Zidovudine and foscarnet each have antiretroviral activity against human immunodeficiency virus (HIV) and, when combined in vitro, inhibit HIV replication in an additive or synergistic fashion. To determine if an in vivo additive or synergistic antiretroviral effect might result from combined therapy, six symptomatic HIV-infected patients were studied who had persistently quantifiable serum HIV p24 antigen despite 9–27 weeks of full-dose oral zidovudine therapy (1200mg/day). These patients were given intravenous foscarnet (30mg/kgevery 8 h) for 2 weeks with continued oral zidovudine for 14days, followed by zidovudine alone for 6 months. Serum p24 antigen concentrations decreased in all six patients during the period of combined therapy by a mean 53% (P = .(05). Subsequently, serum p24 antigen levels rose to the baseline value in four patients after 4–14 weeks. As predicted from in vitro studies, combined treatment with zidovudine and foscamet resulted in an additive in vivo effect, but the effect was transient.</abstract><cop>United States</cop><pub>University Chicago Press</pub><pmid>1828075</pmid><doi>10.1093/infdis/163.6.1219</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1991-06, Vol.163 (6), p.1219-1222 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80571219 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing |
| subjects | Administration, Oral AIDS AIDS related complex AIDS/HIV Antigens Antiretrovirals Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Antivirals Blood plasma Dosage Drug Therapy, Combination Follow-Up Studies Foscarnet Gene Products, gag - blood HIV HIV Antigens - blood HIV Core Protein p24 HIV Infections - drug therapy Humans Infections Infusions, Intravenous Lymphocytes Major Articles Phosphonoacetic Acid - administration & dosage Phosphonoacetic Acid - analogs & derivatives Phosphonoacetic Acid - therapeutic use Viral Core Proteins - blood Zidovudine - administration & dosage Zidovudine - therapeutic use |
| title | In Vivo Additive Antiretroviral Effect of Combined Zidovudine and Foscarnet Therapy for Human Immunodeficiency Virus Infection (ACTG Protocol 053) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A04%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20Vivo%20Additive%20Antiretroviral%20Effect%20of%20Combined%20Zidovudine%20and%20Foscarnet%20Therapy%20for%20Human%20Immunodeficiency%20Virus%20Infection%20(ACTG%20Protocol%20053)&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Jacobson,%20Mark%20A.&rft.date=1991-06&rft.volume=163&rft.issue=6&rft.spage=1219&rft.epage=1222&rft.pages=1219-1222&rft.issn=0022-1899&rft.eissn=1537-6613&rft_id=info:doi/10.1093/infdis/163.6.1219&rft_dat=%3Cjstor_proqu%3E30132536%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16064310&rft_id=info:pmid/1828075&rft_jstor_id=30132536&rfr_iscdi=true |